These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 31805251)

  • 1. Gadolinium Deposition Disease: A New Risk Management Threat.
    Harvey HB; Gowda V; Cheng G
    J Am Coll Radiol; 2020 Apr; 17(4):546-550. PubMed ID: 31805251
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risks and Options With Gadolinium-Based Contrast Agents in Patients With CKD: A Review.
    Rudnick MR; Wahba IM; Leonberg-Yoo AK; Miskulin D; Litt HI
    Am J Kidney Dis; 2021 Apr; 77(4):517-528. PubMed ID: 32861792
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Consensus Guidelines of the French Society of Neuroradiology (SFNR) on the use of Gadolinium-Based Contrast agents (GBCAs) and related MRI protocols in Neuroradiology.
    Lersy F; Boulouis G; Clément O; Desal H; Anxionnat R; Berge J; Boutet C; Kazémi A; Pyatigorskaya N; Lecler A; Saleme S; Edjlali-Goujon M; Kerleroux B; Ben Salem D; Kremer S; Cotton F
    J Neuroradiol; 2020 Nov; 47(6):441-449. PubMed ID: 32565280
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium Deposition and Chronic Toxicity.
    Ramalho J; Ramalho M
    Magn Reson Imaging Clin N Am; 2017 Nov; 25(4):765-778. PubMed ID: 28964466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brain gadolinium deposition after administration of gadolinium-based contrast agents.
    Kanda T; Oba H; Toyoda K; Kitajima K; Furui S
    Jpn J Radiol; 2016 Jan; 34(1):3-9. PubMed ID: 26608061
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute Chelation Therapy-Associated Changes in Urine Gadolinium, Self-reported Flare Severity, and Serum Cytokines in Gadolinium Deposition Disease.
    Maecker HT; Siebert JC; Rosenberg-Hasson Y; Koran LM; Ramalho M; Semelka RC
    Invest Radiol; 2021 Jun; 56(6):374-384. PubMed ID: 33449576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gadolinium deposition in the brain.
    Kanda T; Nakai Y; Oba H; Toyoda K; Kitajima K; Furui S
    Magn Reson Imaging; 2016 Dec; 34(10):1346-1350. PubMed ID: 27613998
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium deposition and the potential for toxicological sequelae - A literature review of issues surrounding gadolinium-based contrast agents.
    Layne KA; Dargan PI; Archer JRH; Wood DM
    Br J Clin Pharmacol; 2018 Nov; 84(11):2522-2534. PubMed ID: 30032482
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gadolinium based contrast agents (GBCA): Safety overview after 3 decades of clinical experience.
    Kanal E
    Magn Reson Imaging; 2016 Dec; 34(10):1341-1345. PubMed ID: 27608608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histology and Gadolinium Distribution in the Rodent Brain After the Administration of Cumulative High Doses of Linear and Macrocyclic Gadolinium-Based Contrast Agents.
    Lohrke J; Frisk AL; Frenzel T; Schöckel L; Rosenbruch M; Jost G; Lenhard DC; Sieber MA; Nischwitz V; Küppers A; Pietsch H
    Invest Radiol; 2017 Jun; 52(6):324-333. PubMed ID: 28323657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gadolinium-based contrast agents - what is the evidence for 'gadolinium deposition disease' and the use of chelation therapy?
    Layne KA; Wood DM; Dargan PI
    Clin Toxicol (Phila); 2020 Mar; 58(3):151-160. PubMed ID: 31663374
    [No Abstract]   [Full Text] [Related]  

  • 12. Gadolinium Deposition in the Brain: Current Updates.
    Choi JW; Moon WJ
    Korean J Radiol; 2019 Jan; 20(1):134-147. PubMed ID: 30627029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gadolinium Deposition and Nephrogenic Systemic Fibrosis: A Radiologist's Primer.
    Mathur M; Jones JR; Weinreb JC
    Radiographics; 2020; 40(1):153-162. PubMed ID: 31809230
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gadolinium-based contrast agents in children.
    Rozenfeld MN; Podberesky DJ
    Pediatr Radiol; 2018 Aug; 48(9):1188-1196. PubMed ID: 30078039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of gadolinium-based contrast agents in neurological disorders.
    Golec W; Jakimów-Kostrzewa A; Mruk B; Jóźwiak S
    Neurol Neurochir Pol; 2020; 54(5):399-409. PubMed ID: 32955099
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and Safety of Gadolinium Based Contrast Agents in Pediatric MR Imaging.
    Holowka S; Shroff M; Chavhan GB
    Indian J Pediatr; 2019 Oct; 86(10):961-966. PubMed ID: 30796704
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gadolinium Deposition: A Study Review.
    Strickler SE; Clark KR
    Radiol Technol; 2021 Jan; 92(3):249-258. PubMed ID: 33472877
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Patient with Reported Gadolinium-Associated Illness.
    Lyapustina T; Goldfine C; Rhyee S; Babu KM; Griswold MK
    J Med Toxicol; 2019 Jan; 15(1):36-44. PubMed ID: 30499040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gadolinium-based contrast agents: A comprehensive risk assessment.
    Fraum TJ; Ludwig DR; Bashir MR; Fowler KJ
    J Magn Reson Imaging; 2017 Aug; 46(2):338-353. PubMed ID: 28083913
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gadolinium Deposition in Neurology Clinical Practice.
    Smith TE; Steven A; Bagert BA
    Ochsner J; 2019; 19(1):17-25. PubMed ID: 30983897
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.